Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.66 Analyst target: $7.25 Upside: 995.17%
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.